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Background: This research paper presents a valid treatment strategy for recurrent glioblastoma multiforme (GBM)
using hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy (HS-IMRT) planned with
11C-methionine positron emission tomography (MET-PET)/computed tomography (CT)/magnetic resonance imaging
(MRI) fusion.
Methods: Twenty-one patients with recurrent GBM received HS-IMRT planned by MET-PET/CT/MRI. The region of
increased amino acid tracer uptake on MET-PET was defined as the gross tumor volume (GTV). The planning target
volume encompassed the GTV by a 3-mm margin. Treatment was performed with a total dose of 25- to 35-Gy,
given as 5- to 7-Gy daily for 5 days.
Results: With a median follow-up of 12 months, median overall survival time (OS) was 11 months from the start of
HS-IMRT, with a 6-month and 1-year survival rate of 71.4% and 38.1%, respectively. Karnofsky performance status
was a significant prognostic factor of OS as tested by univariate and multivariate analysis. Re-operation rate was
4.8% for radiation necrosis. No other acute or late toxicity Grade 3 or higher was observed.
Conclusions: This is the first prospective study of biologic imaging optimized HS-IMRT in recurrent GBM. HS-IMRT
with PET data seems to be well tolerated and resulted in a median survival time of 11 months after HS-IMRT.
Keywords: Recurrent glioblastoma multiforme, Hypofractionated stereotactic radiotherapy, Intensity modulated
radiation therapy, 11C-methionine PETBackground
In recurrent gliomas retreated with radiation therapy, pre-
cise dose delivery is extremely important in order to reduce
the risk of normal brain toxicity. Recently, novel treatment
modalities with increased radiation dose-target conformal-
ity, such as intensity modulated radiation therapy (IMRT),* Correspondence: kz-surg.21@gero-hp.jp
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unless otherwise stated.have been introduced [1-4]. While IMRT has superior tar-
get isodose coverage compared to other external radiation
techniques in scenarios involving geometrically complex
target volumes adjacent to radiosensitive tissues, planning
and delivery in IMRT are resource intensive and require
specific and costly software and hardware.
Gross tumor volume (GTV) delineation in gliomas has
been traditionally based on computed tomography (CT)
and magnetic resonance imaging (MRI). However, 11C-
methionine positron emission tomography (MET-PET)
for high-grade gliomas was recently demonstrated to
have an improved specificity and sensitivity and is thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment planning [5-8]. In previous studies using MET-PET/
MRI image fusion, we demonstrated that biologic im-
aging helps to detect tumor infiltration in regions with a
non-specific MRI appearance in a significant number of pa-
tients [9-11]. Moreover, non-specific post-radiotherapeutic
changes (e.g., radiation necrosis, gliosis, unspecific blood–
brain barrier disturbance) could be differentiated from
tumor tissue with a higher accuracy [12-14]. A recent
study demonstrated that MET-PET could improve the
ability to identify areas with a high risk of local failure in
GBM patients [15].
Based on the prior PET studies, we hypothesized that
an approach of hypofractionated stereotactic radiother-
apy by IMRT (HS-IMRT) with the use of MET-PET data
would be an effective strategy for recurrent GBM. This
prospective study was designed to measure the acute and
late toxicity of patients treated with HS-IMRT planned by
MET-PET, response of recurrent GBM to this treatment,




Patients were recruited from September 2007 to August
2011. Adult patients (aged ≥ 18 years) with histopatho-
logic confirmation of GBM who had local recurrent
tumor were eligible. Primary treatment consisted of sub-
total surgical resection in all patients. All patients had a
Karnofsky performance status (KPS) ≥ 60 and were pre-
viously treated with external postoperative radiotherapy
to a mean and median dose of 60 Gy (range 54 Gy–68
Gy) with concomitant and adjuvant Temozolomide
(TMZ) chemotherapy. Additional inclusion criteria con-
sisted of the following: age 18 years or older; first macro-
scopical relapse at the original site; and adequate bone
marrow, hepatic, and renal function. In all cases, a
multidisciplinary panel judged the resectability of the le-
sion before inclusion in this study. Thus patients with
non-resectable lesions were included in the study.
Study design
This prospective nonrandomized single-institution study
was approved by the Department of Radiation Oncology
of Kizawa Memorial Hospital Institutional Review Board.
Informed consent was obtained from each subject after
disclosing the potential risks of HS-IMRT and discussion
of potential alternative treatments. Baseline evaluation
included gadolinium-enhanced brain MRI and MET-PET,
complete physical and neurological examination, and
blood and urine tests within 2 weeks before treatment.
After completion of HS-IMRT, patients underwent a
physical and neurological examination and a repeat brain
MRI and MET-PET. TMZ chemotherapy was continuedin a manner consistent with standard clinical use after
HS-IMRT course.
Imaging: CT
CT (matrix size: 512 × 512, FOV 50 × 50 cm) was per-
formed using a helical CT instrument (Light Speed;
General Electric, Waukesha, WI). The patient head was
immobilized in a commercially available stereotactic mask,
and scans were performed with a 2.5-mm slice thickness
without a gap.
Imaging: MRI
MRI (matrix size: 256 × 256, FOV 25 × 25 cm) for radi-
ation treatment planning was performed using a 1.5-T
instrument (Light Speed; General Electric). A standard
head coil without rigid immobilization was used. An axial,
three-dimensional gradient echo T1-weighted sequence
with gadolinium and 2.0-mm slice thickness were ac-
quired from the foramen magnum to the vertex, perpen-
dicular to the main magnetic field.
Imaging: MET-PET
An ADVANCE NXi Imaging System (General Electric
Yokokawa Medical System, Hino-shi, Tokyo), which pro-
vides 35 transaxial images at 4.25-mm intervals, was used
for PET scanning. A crystal width of 4.0 mm (transaxial)
was used. The in-plane spatial resolution (full width at
half-maximum) was 4.8 mm, and scans were performed in
a standard two-dimensional mode. Before emission scans
were performed, a 3-min transmission scan was per-
formed to correct photon attenuation using a ring source
containing 68Ge. A dose of 7.0 MBq/kg of MET was
injected intravenously. Emission scans were acquired for
30 min, beginning 5 min after MET injection. During
MET-PET data acquisition, head motion was continuously
monitored using laser beams projected onto ink markers
drawn over the forehead skin and corrected as neces-
sary. PET/CT and MRI volumes were fused using com-
mercially available software (Syntegra, Philips Medical
System, Fitchburg, WI) using a combination of automatic
and manual methods. Fusion accuracy was evaluated by a
consensus of 3 expert radiologists with 15 years of experi-
ence using anatomical fiducials such as the eyeball, lacri-
mal glands, and lateral ventricles.
Radiation technique
Target volumes were delineated on the registered PET/
CT-MRI images and were used to plan HS-IMRT delivery.
In this preliminary study, GTV was defined as using an
area of high uptake on MET-PET (Figure 1). This high-
uptake region was defined using a threshold value for the
lesion versus normal tissue counts of radioisotope per
pixel index of at least 1.3. A previous study with high-
grade gliomas, comparing the exact local MET uptake
A B
Figure 1 An example of a target planned for a hypofractionated stereotactic radiotherapy using intensity modulated radiation
therapy. (A) Contrast-enhanced T1-weighted magnetic resonance imaging. (B) 11C-methionine positron emission tomography (MET-PET). Gross
tumor volume was defined as the region with high MET uptake (yellow line). The threshold for increased MET uptake was set to ≥1.3 in the
contiguous tumor region.
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strated a sensitivity of 87% and specificity of 89% for the
detection of tumor tissue at the same threshold of 1.3-fold
MET uptake relative to normal brain tissue [16]. Further,
this threshold was validated in a study using diffusion
tensor imaging in comparison with MET uptake [17].
Although the delineation of GTV was done by using
the automatic contouring mode (Philips Pinnacle v9.0
treatment planning system), the final determination of
GTV was confirmed by consensus among 3 observers
based on the co-registered MRI and PET data. The PET/
MRI fusion image was positioned properly by CT scans
equipped with Helical TomoTherapy (TomoTherapy Inc.,
Madison, WI). Finally, the GTV was expanded uniformly
by 3 mm to generate the planning target volume (PTV).
The prescribed dose for re-irradiation was based on tumor
volume, prior radiation dose, time since external post-
operative radiotherapy, and location of the lesion with
proximity to eloquent brain or radiosensitive structures.
Radiosensitive structures, including the brainstem, optic
chiasm, lens, optic nerves, and cerebral cortex, were out-
lined, and dose-volume histograms for each structure were
obtained to ensure that doses delivered to these structures
were tolerable. Considering these different conditions, the
dose for PTV was prescribed using the 80-95% isodose
line, and the total doses were arranged from 25 Gy to 35
Gy in each patient. The dose maps and dose-volume histo-
grams of a representative case are illustrated in Figure 2.Chemotherapy
After HS-IMRT course, a dose of 200 mg/m2/day for
5 days with TMZ chemotherapy was administered. Cy-
cles were repeated every 28 days with 3 or more cycles
after HS-IMRT. Treatment was discontinued when un-
equivocal progression or severe toxicity occurred. TMZwas not administrated in patients who refused treatment
or did not meet inclusion criteria. Patient inclusion cri-
teria for TMZ chemotherapy consisted of the following:
KPS score 50 or higher; evidence of good maintenance
of major organ function (bone marrow, liver, kidney,
etc.) in routine laboratory studies; expected to survive
more than 3 months.Follow-up
Regular serial neurological and radiological examinations
were initially performed at 1 month after completion of
treatment and then every 2 months thereafter or in the
event of neurological decay. Follow-up examinations in-
cluded MRI and MET-PET imaging. If the MRI revealed
further enlargement of the enhanced mass, the lesion
was diagnosed as “local progression”, and the day on
which MRI first revealed lesion enlargement was defined
as the date of progression. However, in cases with low
MET uptake on PET in the MRI-enhanced lesion, the
diagnosis was changed to “radiation necrosis”. The cri-
terion of MET-PET differential diagnosis between local
progression and radiation necrosis was utilized in a pre-
vious MET-PET study by Takenaka et al. [18]. However,
all patients couldn’t be applied with PET examination in
the follow up study. In cases without PET examination,
diagnosis of radiation necrosis was based on pathologic
examination or clinical course. Cases in which lesions
showed spontaneous shrinkage or decreased in size during
corticosteroid treatment were also defined as “radiation
necrosis”. A diagnosis of “distant failure” was defined
as the appearance of a new enhanced lesion distant
from the original tumor site. Either local progression or
distant failure was defined as disease progression. Acute
and late toxicities were determined based on the Common
Terminology Criteria for Advance Events (version 4).






Figure 2 A dose map and dose-volume histogram of a representative case. Prescribed dose for planning target volume (PTV) and the doses
of organs at risk were demonstrated.
Miwa et al. Radiation Oncology 2014, 9:181 Page 4 of 9
http://www.ro-journal.com/content/9/1/181Statistical analysis
Survival events were defined as death from any cause for
OS and as disease progression for progression-free sur-
vival (PFS). OS and PFS were analyzed from the date of
HS-IMRT to the date of the documented event using
the Kaplan-Meier method. Tumor- and therapy-related
variables were tested for a possible correlation with sur-
vival, using the Log-rank test. Variables included age
(≥50 vs. <50), KPS (≥70 vs. <70), and combined TMZ
chemotherapy (“yes” vs. “no”). P-values of less than 0.05
were considered significant. Prognostic factors were fur-












Abbreviations: KPS Karnofsky performance status, TMZ temozolomide.Results
Twenty-one patients (18 men, 3 women) with histologi-
cally confirmed GBM were enrolled in this trial (Table 1).
The median patient age was 53.9 years (range 22–76),
and median KPS was 80 (range 60–90).
The median elapsed time between external postopera-
tive radiotherapy and study enrollment was 12 months
(range, 3–48 months). HS-IMRT was performed in 5
fractions, keeping a total dose for the PTV at 25 Gy in 6
patients, 30 Gy in 11 patients, and 35 Gy in 4 patients,
given as 5- to 7-Gy daily over a period of 5 days. The
average PTV was 27.4 ± 24.1 cm3 (3.4 - 102.9 cm3). All21 patients completed the prescribed HS-IMRT course.
Overall, thirteen patients (62%) received combined mo-
dality treatment with TMZ.Toxicity assessment
No patients demonstrated significant acute toxicity, and
all patients were able to complete the prescribed radi-
ation dose without interruption. In the late phase, Grade
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the lesion was decreased in size during corticosteroid
treatment. One patient who received a dose of radiation of
25.0 Gy, experienced Grade 4 radiation necrosis in the
form of mental deterioration 4 months after HS-IMRT. In
this case, a second necrotomy was required 5 months after
HS-IMRT. Although after a second surgery, the patient’s
clinical condition was stable for a long period, disease
progression occurred 40 months after HS-IMRT, causing
death. The actuarial reoperation rate was 4.8% for radi-
ation necrosis.Outcomes
With a median follow-up of 12 months, the median OS
was 11 months from the date of HS-IMRT, with a 6-
month and 1-year survival rate of 71.4% and 38.1%, re-
spectively (Figure 3A). The survival rates by age, KPS,
and TMZ chemotherapy are shown in Figure 4A-C. OS
of patients with KPS 70 or over was 12 months versus
5 months for patients with KPS less than 70. KPS was a
significant prognostic factor of OS as tested by univari-
ate analysis (p < 0.001). OS of patients who received






































A  Overall surviva
B Progression-fre
Figure 3 (A) Overall survival and (B) Progression-free survival for all p
time was 11 months, and the median progression-free survival time was 66 months for patients who did not receive chemotherapy.
The differences between the two groups approached sig-
nificance (p = 0.079). In the multivariate model, only KPS
remained statistically significant (p = 0.005) (Table 2).
The median PFS was 6 months from the date of HS-
IMRT treatment, with a 6-month and 1-year survival rate
of 38.1% and 14.3%, respectively (Figure 3B). KPS was the
significant prognostic factor for PFS as tested by univariate
analysis (p = 0.016). On multivariate analysis, none of the
variables were significantly predictive of PFS (Table 3).
A representative case is shown in Figure 5, in which a
follow-up MET-PET scan was performed to improve the
diagnostic accuracy.Discussion
Recently, much work has been performed on various frac-
tionation regimens and dose escalation with IMRT for
GBM. These studies reveal relatively favorable survival re-
sults [1-4], although a distinct advantage over conventional
radiation therapy has not been demonstrated. However,
if a precise conformal treatment technique such as HS-
IMRT is utilized, and a greater biologic dose to the infil-
trating tumor is achieved through hypo-fractionation, it25 30 35 40 45





atients from the date of re-irradiation. The median overall survival








































































Figure 4 Overall survival rates among different subgroups by (A) age, (B) Karnofsky performance status (KPS), and (C) combined
temozolomide (TMZ) chemotherapy.
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increase patient survival without increasing morbidity. To
meet these requirements, the contouring of the target vol-
ume is of critical importance.
PET is a newer imaging method that can improve the
visualization of biological processes. In recent PET stud-
ies, analysis of the metabolic and histologic character-
istics provided evidence that regional high MET uptake


















Yes 12 0.079 0.581
No 6
Abbreviations as in Table 1.
Statistical analyses were performed with *Log - rank test and †Cox’s proportional
hazards model.Furthermore, nonspecific post-therapeutic changes could
be differentiated from tumor tissue with a higher accuracy
[12-14]. These findings support the notion that comple-
mentary information derived from MET uptake may be
helpful in developing individualized, patient-tailored ther-
apy strategies in patients with recurrent GBM.
This prospective study was designed to measure the
acute and late toxicity of patients treated with HS-IMRT
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Abbreviations as in Table 1.





Figure 5 Recurrent glioblastoma multiforme (GBM) in a 55-year-old man before and after hypofractionated stereotactic radiotherapy
by intensity modulated radiation therapy (HS-IMRT). Before HS-IMRT, two enhanced lesions (long and short arrow) were demonstrated in the
left temporal lobe on T1-weighted magnetic resonance imaging (A). 11C-methionine positron emission tomography (MET-PET) demonstrated a
MET high-uptake on the region of short arrow, which was defined as the Gross Tumor Volume (red line) (B). 5 months after HS-IMRT, there was
no tumor recurrence on the lesion (long arrow, C & D). The enhanced lesion (short arrow) was increased in size (C), although MET uptake
decreased relative to normal tissue, which suggested a necrotic change in the irradiated region (D). The patient had no neurologic deficits or
quality of life issues. KPS was 90%.
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after treatment. We found that the OS rate from re-
irradiation was 11 months and that the 6-month and
1-year OS rates were 71.4% and 38.1%, respectively
(Figure 3). The survival results of our study appeared to
be favorable compared to prior studies using other hypo-
fractionated stereotactic radiotherapy in recurrent ma-
lignant glioma [19-22]. Also, we observed an improved
toxicity profile, suggesting that hypofractionated stereotac-
tic radiotherapy should be considered standard salvage
therapy for previously irradiated high-grade gliomas [23].
We hypothesized that MET-PET/CT/MRI image fusion
could facilitate target volume delineation and normal
tissue sparing. This might lead to an improved thera-
peutic ratio, especially in pre-treated patients, in which
post-therapy changes in CT or MRI, as with contrast en-
hancement, are difficult to distinguish from tumor recur-
rence (Figure 5).
In our study, KPS ≥ 70% was associated with longer pa-
tient survival, as previously described for recurrent GBM
[21]. In addition, we observed a trend toward a beneficial
effect on OS when combining TMZ chemotherapy(Figure 4C, Table 2). We estimated that the addition
of TMZ might be particularly effective if the radiation
dose to normal brain tissue was limited by better tar-
geting. However, the impact of TMZ along with the
methylation status of the O-6-methylguanine-DNA meth-
yltransferase (MGMT) on survival was not systematically
evaluated in the present study. This study has a selection
bias which necessitates prospective studies, as the pa-
tients with methylated MGMT or who were in better
clinical condition were more likely to have received adju-
vant TMZ chemotherapy. Nevertheless, the results of
this study support our initial work and further estab-
lish the efficacy of this HS-IMRT regimen combined with
TMZ.
Both single-fraction stereotactic radiosurgery and brachy-
therapy have been reported to have modest utility as pal-
liative salvage interventions; however, both have been
associated with high rates of re-operation because of the
associated toxicity [24,25]. Our initial experience with
HS-IMRT used the 5- to 7-Gy fractions to a maximum of
35 Gy and reported an actuarial reoperation rate of 4.8%
for radiation necrosis, providing additional support that
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ion, MET-PET/CT/MR image fusion could facilitate tar-
get volume delineation and normal tissue sparing, which
might lead to an improved therapeutic ratio. MET-PET/
CT/MR image fusion planning, which examines biological
behavior in re-irradiation, seems not only to decrease the
likelihood of geographical misses in target volume defin-
ition, but also to facilitate normal tissue sparing and tox-
icity reduction, especially when conformal treatment
technique such as HS-IMRT is implemented.
Conclusions
This is the first prospective study using biologic imaging
to optimize HS-IMRT using MET-PET/CT/MRI image
fusion in recurrent GBM. A low frequency of side effects
was observed. HS-IMRT with PET data seems to be well
tolerated and resulted in a median survival time of
11 months after HS-IMRT, although a properly designed
randomized trial are necessary to firmly establish whether
the present regimen is superior to the other treatment
methods for recurrent GBM.
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